

Perspective

TGF- β : the missing link in CD4⁺CD25⁺ regulatory
T cell-mediated immunosuppression

WanJun Chen*, Sharon M. Wahl

*Cellular Immunology Section, Oral Infection and Immunity Branch, NIDCR, NIH, Room 332,
Building 30, Bethesda, MD 20892-4352, USA*

Abstract

A unique population of CD4⁺ T lymphocytes that constitutively express CD25 has been recognized as anergic/suppressor cells. While the immunosuppressive activity of these CD4⁺CD25⁺ cells has been validated and implicated in tolerance, autoimmunity, transplantation, cancer and infectious diseases, the mechanism(s) by which they function still remains controversial. Although the involvement of TGF- β was initially discounted, emerging evidence now links this cytokine with CD4⁺CD25⁺ T cell-mediated suppression of antigen-activated T cells. In this perspective, we summarize recently published studies, as well as our own data, which shed light on how cell membrane-bound TGF- β can deliver a regulatory signal to target cells via a contact-dependent process. Moreover, suppressor T cell function is a complex process, tightly regulated by multiple factors, including IL-2, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and glucocorticoid induced TNF receptor (GITR). Collectively, multiple previously unconnected puzzle pieces are beginning to be linked into a more coherent, albeit incomplete picture of CD4⁺CD25⁺ T cell-mediated suppression.

Published by Elsevier Science Ltd.

Keywords: Suppressor cells; Autoimmune diseases; Tolerance; Smad; TGF- β receptor type II

Following the original identification of a small, but powerful, population of CD4⁺CD25⁺ T cells which can dramatically suppress immune responsiveness, there has been an enormous effort to dissect the mechanisms by which these cells exert their suppressive prowess. In a short period of time, CD4⁺CD25⁺ regulatory T cells have generated so much interest in immunology because of their recognized importance in tolerance, autoimmune diseases, transplantation, cancer and infectious diseases. Nonetheless, the mechanisms underlying their ability to suppress immunity remain ill defined and hotly contested. New studies are providing pieces to this perplexing puzzle, including a role for TGF- β , and are linking several controversial and previously unconnected results into an emerging coherent picture.

First described by Sakaguchi et al. [1], these regulatory T cells, with their potent suppressive activity on normal responder T cell function in vivo and in vitro, are CD4 positive and constitutively express CD25 (IL-2 receptor alpha chain) on their cell surface. Produced in the thymus, approximately 5–10% of the CD4⁺ T cells exiting the thymus belong to this phenotype (Fig. 1). CD4⁺CD25⁺ T cells circulate in watchful anticipation of an inflammatory/immune response where they will become activated to exhibit their suppressive potential. Functionally, these suppressor T cells are anergic

and require T cell receptor (TCR) activation and cell contact for optimal inhibition of responder (CD4⁺CD25⁻) and self-reactive T cells, as they orchestrate peripheral tolerance.

Although most investigators agree that cell contact between suppressor and responder T cells is central to suppressor activity, the underlying molecular events remain a point of contention. Several studies have demonstrated that CD4⁺CD25⁺ T cells produce elevated levels of TGF- β in both mice and humans. Furthermore, independent studies [2–4] have demonstrated that anti-TGF- β 1 antibody can reverse the suppression by CD4⁺CD25⁺ T cells in a dose dependent manner. A key to understanding the cell contact-dependent immunosuppression by the suppressor T cells was the recognition that the CD4⁺CD25⁺ T cells express surface membrane-bound TGF- β . Not only do CD4⁺CD25⁺ regulatory T cells express latent TGF- β [3], but these cells also bear TGF- β in its active configuration on the cell surface [4]. A defining piece of the puzzle was inserted when it was shown that enhanced TGF- β signaling receptors reside on the membrane of these cells. Thus, this population of cells constitutively expresses the signaling TGF- β receptor type II (T β RII) (Chen et al., submitted for publication), in addition to increased TGF- β , which underscores the potential for autocrine and/or paracrine receptor–ligand interactions (Fig. 2). Since the primary effect of TGF- β -T β RII signaling in T cells is to block IL-2

* Corresponding author.




Fig. 1. Peripheral immunologic self-tolerance maintained by $CD4^+CD25^+$ "anergic/suppressor" T cells. A small number of $CD4^+$ T cells constitutively expressing CD25 (5–10% of total $CD4^+$ T cells) are generated in the thymus, and migrate into the periphery to regulate normal immune responses and maintain self-tolerance. Although high affinity self-reactive T cells are typically deleted in the thymus, some may escape to the periphery. In cooperation with activation induced T cell apoptosis, anergy and suppressive cytokines, $CD4^+CD25^+$ suppressor T cells regulate the balance between immunity and tolerance to safeguard the host against autoimmunity and immunopathology.

production [5–8], the coordinate expression of both cell surface-associated active TGF- β and T β RII on the suppressor cells may explain why these cells are functionally anergic and lack IL-2 expression upon TCR stimulation. Moreover, fulfilling another tenet of suppressor T cell function, TCR engagement augments the expression of both TGF- β and T β RII, enhancing this self-inflicted anergy.




Fig. 2. Mechanism of $CD4^+CD25^+$ -mediated immunosuppression. $CD4^+CD25^+$ T cell suppression requires T cell receptor (TCR) engagement and cell-cell contact with the target cells. Once activated, $CD4^+CD25^+$ cells inhibit $CD4^+CD25^-$ responder T cells and/or other cells (e.g. B cells) in a non-specific manner, which can be reversed by high dose IL-2 or anti-CD28 stimulation. Freshly isolated $CD4^+CD25^+$ T cells express cell surface TGF- β and TGF- β receptor II (T β RII), which are upregulated by TCR stimulation in the presence of antigen presenting cells (APCs). Naïve $CD4^+CD25^-$ responder T cells express neither TGF- β nor T β RII, but become positive for T β RII after TCR stimulation. The co-expression of TGF- β and T β RII on $CD4^+CD25^+$ cells may be responsible for their anergic state. The interaction between surface TGF- β on $CD4^+CD25^+$ suppressor and T β RII on $CD4^+CD25^+$ responder may provide the molecular mechanism by which the "suppressors" function.

While the existence of TGF- β on the surface of $CD4^+CD25^+$ T cells offers a clue for the generally recognized cell-contact dependence and antigen non-specificity features associated with suppressor T cell function [9,10], it does not address the mechanism whereby TGF- β drives the suppression of T β RII-negative responder T cells. TGF- β is a cytokine with known involvement in the regulation of growth inhibition, apoptosis, differentiation and/or suppression of multiple cell types [11–13], yet the documented requirement for cell contact in T cell suppressor activity initially appeared incompatible with this soluble cytokine. Very compelling then was the unanticipated demonstration of upregulation of T β RII on the responder cells following triggering of their TCR, thereby establishing a connection through which suppressor cell derived TGF- β can bind to activated responder cells and transduce contact-dependent suppressive signals [4].

TGF- β mediates its effects on cells through a heteromeric complex consisting of type I (RI) and type II (RII) receptor components. T β RI and T β RII are serine–threonine kinases that phosphorylate downstream signaling proteins once TGF- β binds to T β RII, which in turn recruits and phosphorylates T β RI. The receptor complex then propagates the signal through the phosphorylation of cytosolic proteins, including the Smad proteins, Smad2 and Smad3 [14] (Fig. 3). Once activated, Smad2 and Smad3 form a hetero-oligomeric complex, typically including the co-Smad4, and translocate to the nucleus where they modulate transcription of specific genes through *cis*-regulatory Smad-binding sequences and through binding with other transcription factors [15,16]. Of significance was the evidence that $CD4^+CD25^+$ suppressor T cells induce increased phosphorylation of Smad2/3 in $CD4^+CD25^-$ responder T cells upon cell contact (Chen et al., submitted for publication), confirming engagement




Fig. 3. TGF- β signaling pathway and role of GITR to reverse suppression. TGF- β binds its receptor II (RII), potentially in the context of receptor III (RIII), to phosphorylate TGF- β receptor I (RI). This ligand–receptor complex initiates a signaling cascade involving phosphorylation of Smad2 and/or 3 (P-Smad2/3). In complex with the common Smad4, P-Smad2/3 translocates to the nucleus to regulate gene transcription. CD4⁺CD25⁺ suppressors also express GITR on their membranes and engagement of this receptor with anti-GITR antibody antagonizes TGF- β signal transduction by inhibiting Smad2/3 phosphorylation to block suppression.

of the TGF- β -T β RII signaling pathway. Moreover, recent studies have revealed that multiple intersecting pathways may contribute to the TGF- β signaling cascade [15]. Consistent with involvement of multiple pathways, mice lacking only Smad3 survive much longer than mice deficient in the ligand, TGF- β 1 (TGF- β 1^{−/−}), which develop rapid and massive T cell activation and inflammation culminating in their early demise. Since Smad3 null CD4⁺CD25[−] responder T cells are inhibited directly by exogenous TGF- β (Chen et al., unpublished data), to the same extent as wild-type CD4⁺CD25⁺ suppressor T cells [17], it is likely that, at a minimum, Smad2, in addition to Smad3 is engaged in the process of suppression. Nonetheless, the finding that responder T cells become T β RII positive upon activation provides the missing link by which suppressor T cell-associated TGF- β interacts with and engages its cognate receptor on the responder T cells to efficiently block IL-2 production and proliferation. Moreover, the upregulation of membrane active TGF- β and T β RII on the suppressor cells after TCR and antigen presenting cell (APC) stimulation [4] provides insight into the necessity of activation for the suppressor cells to function optimally [9,10]: a minimal binding threshold between TGF- β on the suppressor and T β RII on the responder may be required to deliver a sufficient negative signal to thwart IL-2 production and the proliferative response.

Since CD4⁺CD25⁺ T cells express surface TGF- β , implicated in the suppression mechanism, one might expect to see that freshly isolated CD4⁺CD25⁺ T cells from TGF- β 1^{−/−} mice have no suppressive effect. Indeed, TGF- β 1^{−/−} CD4⁺CD25⁺ T cells in vitro do not inhibit

responder cells at normal suppressor/responder ratios (Chen et al., unpublished data). However, with increasing numbers of TGF- β 1 null CD4⁺CD25⁺ T cells (5–10-fold), some inhibitory activity can be detected (unpublished), as recently reported [17], implicating potential alternative pathways of suppression. In this regard, the phenotype of freshly isolated CD4⁺CD25⁺ TGF- β 1^{−/−} T cells is distinct from their wildtype counterparts. The majority of TGF- β 1^{−/−} CD4⁺CD25⁺ T cells are CD62L^{low} (a phenotypic marker of activated/memory cells) compared to only a small percentage of wildtype cells, reflecting their constitutive activation [18]. This phenotype of CD4⁺CD25⁺ T cells is seen in 6–7-day-old TGF- β 1^{−/−} mice prior to overt evidence of their autoimmune-like inflammation [19]. Clearly, the TGF- β null CD4⁺CD25⁺ T cell populations are unique and/or may express alternative regulatory molecules. Although there are temporal, spatial and functional differences between TGF- β 1 and its homologs, TGF- β 2 and TGF- β 3, in vivo, both TGF- β 2 and TGF- β 3 exhibit suppression in vitro and may play a role in the absence of TGF- β 1. A compensatory increase in other immunoregulatory factors, such as IL-10, must also be considered. In the co-culture system, the hypersensitivity of TGF- β 1^{−/−} T cells to apoptosis [19] may trigger wildtype APCs to release TGF- β [20], which may contribute to suppression. Collectively, the jury is still out on how TGF- β null T cells promote suppression. Additionally, the ability of high numbers of CD4⁺CD25⁺ TGF- β 1^{−/−} T cells to effect suppression must be viewed with caution since maternal transfer of TGF- β [21] and its passive binding to these cells cannot be excluded. Nonetheless, as clearly observed in vivo, in the absence of TGF- β ,

there is insufficient suppression, and the mice succumb to fatal autoimmune-like disease.

Multiple factors may impact on the ability of CD4⁺CD25⁺ suppressor/anergic T cells to orchestrate suppression of responder and/or autoreactive T cells. Among these is IL-2, since culture IL-2 levels determine how or if TGF- β affects T cell proliferation [5,22], and high doses of IL-2 and/or anti-CD28 stimulation reverse CD4⁺CD25⁺ T cell anergy and suppressive activity [23]. In this same vein, our findings that exogenous IL-2 does not affect cell surface-associated TGF- β on suppressor CD4⁺CD25⁺ T cells clarifies the paradox that high dose IL-2 can reverse their anergic state, but preserve their suppressive ability [9,10].

Another molecule which appears to impact on TGF- β -mediated suppression is cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), a negative co-stimulatory molecule for T cell activation, constitutively expressed in CD4⁺CD25⁺ T cells [24]. Although two initial reports provided evidence that CTLA-4 engagement is responsible for CD4⁺CD25⁺ T cell function [2,25], the molecular mechanisms by which CTLA-4 signaling contributes to the suppression remain unknown. The functional link between CTLA-4 signaling and TGF- β production in CD4⁺ T cells was first documented in 1998 [26], has been confirmed in murine and human CD4⁺ T cells [27–29], and was recently associated with CD4⁺CD25⁺ T cells [3]. Linking these observations, we demonstrated that CTLA-4 engagement upregulates cell surface active TGF- β and T β RII expression on CD4⁺CD25⁺ suppressor T cells [4]. In a surprising observation, we also found that CTLA-4 on the responder T cells contributes to the suppressive sequelae, since blocking CTLA-4 also downregulates T β RII on activated CD4⁺CD25⁺ responder T cells (Chen et al., submitted for publication). This scenario may mitigate responder cell vulnerability to suppression. Although the mechanism by which CTLA-4 regulates TGF- β and T β RII expression remains an unresolved, but captivating question, a functional linkage between CTLA-4 and TGF- β signaling is consistent with the known negative CTLA-4 signal in the regulation of CD4⁺ T cells.

The powerful activity of these CD4⁺CD25⁺ regulatory cells necessitates a counterbalance, and recent studies [30,31] have identified a surface molecule, the glucocorticoid induced TNF receptor (GITR), which may serve this purpose. Reportedly, engagement of the GITR on CD4⁺CD25⁺ T cells abrogates their suppressive ability. Signaling rather than blocking of GITR on CD4⁺CD25⁺ suppressor T cells appears responsible for disengaging suppression, since an anti-GITR antibody, which engages the receptor, enhances IL-2 induced-proliferation of CD4⁺CD25⁺ T cells [31], without affecting CD4⁺CD25⁺ T cells. Not surprisingly, in light of the dominant role for TGF- β in suppression, reversal of CD4⁺CD25⁺ T cell anergy and suppression invoked by engagement of GITR involves an intermediate step of inhibition/prevention of TGF- β signaling as manifested by blunted Smad2/3 phosphorylation (Fig. 3) (Chen et al., submitted for publication).

While still mechanistically enigmatic, the inhibition of CD4⁺CD25⁺ responder T cell IL-2 production by suppressor cell membrane-bound TGF- β and/or other factors such as TNF-related activation induced cytokine and receptor activator of NF κ B (TRANCE-RANK) [32], T cell negative regulator Tob [33], Th1 transcription factor T-bet [34] and IL-10 [35] may impact on or modify the outcome of GITR signaling of CD4⁺CD25⁺ T cells. A likely cross-talk between GITR and Smad2/3 signaling offers provocative insight into the balance between T cell activation and suppression.

In short, the emerging data link multiple unconnected puzzle pieces into a more coherent, albeit yet incomplete picture of CD4⁺CD25⁺ T cell-mediated suppression. CD4⁺CD25⁺ suppressor, but not CD4⁺CD25⁺ responder T cells, not only express cell surface TGF- β , but also T β RII, a key receptor for TGF- β signaling. On the other hand, the responder T cells become T β RII-positive after TCR stimulation, thereby becoming susceptible to TGF- β upon cell contact as manifested by enhanced phosphorylation of Smad2/3. Collectively, these findings provide molecular evidence in support of the accepted unique features of CD4⁺CD25⁺ suppressor T cells, including anergic to TCR stimulation, cell contact dependency, antigen non-specific suppression and a requirement for TCR engagement. In addition, exogenous IL-2 reverses anergy without altering surface TGF- β to preserve CD4⁺CD25⁺ suppressive ability. While CTLA-4 engagement promotes suppression by enhancing cell surface-associated TGF- β and T β RII, GITR stimulation serves as a counterbalance, inhibiting TGF- β -mediated signaling to blunt immunosuppression. As these pieces are fit into the puzzle, our understanding of the fundamental mechanisms by which CD4⁺CD25⁺ T cells orchestrate suppression and mediate immune tolerance evolves. Since characterization of the CD4⁺CD25⁺ suppressor T cells appears central to defining aberrancies in autoimmunity, transplantation, cancer and HIV/AIDS, continued exploration of this population will uncover potential regulatory pathways in the treatment of multiple immunopathological conditions.

References

- [1] Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α -chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* 1995;155:1151–64.
- [2] Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. *J Exp Med* 2000;192:295–302.
- [3] Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β . *J Exp Med* 2001;194:629–44.
- [4] Chen W, et al. A functional link between CTLA-4 and cell surface-associated TGF- β in CD4⁺CD25⁺ suppressor T cell-mediated immunosuppression. *FASEB J* 2002;16:763.6.

- [5] Kehrl JH, et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. *J Exp Med* 1986;163:1037–50.
- [6] Seder RA, et al. Factors involved in the differentiation of TGF- β -producing cells from naive CD4⁺ T cells: IL-4 and IFN- γ have opposing effects, while TGF- β positively regulates its own production. *J Immunol* 1998;160:5719–28.
- [7] Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. *Immunity* 2001;14:715–25.
- [8] Wahl SM, et al. Transforming growth factor- β is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. *J Immunol* 1988;140:3026–32.
- [9] Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. *Cell* 2000;101:455–8.
- [10] Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. *J Exp Med* 2001;193:F41–6.
- [11] Sporn MB. TGF-beta: 20 years and counting. *Microb Infect* 1999;1:1251–3.
- [12] Chen W, Wahl SM. TGF-beta: receptors, signaling pathways and autoimmunity. *Curr Dir Autoimmun* 2002;5:62–91.
- [13] Gorelik L, Flavell RA. Transforming growth factor-beta in T cell biology. *Nat Rev Immunol* 2002;2:46–53.
- [14] Massague J. TGF- β signal transduction. *Annu Rev Biochem* 1998;67:753–91.
- [15] Roberts AB. The ever-increasing complexity of TGF-beta signaling. *Cytokine Growth Factor Rev* 2002;13:3–5.
- [16] Genestier L, Kasibhatla S, Brunner T, Green DR. Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. *J Exp Med* 1999;189:231–9.
- [17] Piccirillo CA, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. *J Exp Med* 2002;196:237–46.
- [18] Christ M, et al. Immune dysregulation in TGF- β 1 deficient mice. *J Immunol* 1994;153:1936–46.
- [19] Chen W, et al. Requirement for transforming growth factor beta1 in controlling T cell apoptosis. *J Exp Med* 2001;194:439–54.
- [20] Fadok VA, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. *J Clin Invest* 1998;101:890–8.
- [21] Letterio JJ, et al. Maternal rescue of transforming growth factor- β null mice. *Science* 1994;264:1936–8.
- [22] Swain SL, Huston LG, Tonkonogy S, Weinberg A. Transforming growth factor- β and IL-4 cause helper T cell precursors develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. *J Immunol* 1991;147:2991–3000.
- [23] Thornton AM, Shevach EM. CD4⁺CD25⁺ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. *J Exp Med* 1998;188:287–96.
- [24] Salomon B, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4⁺CD25⁺ immunoregulatory T cells that control autoimmune diabetes. *Immunity* 2000;12:431–40.
- [25] Takahashi T, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. *J Exp Med* 2000;192:303–10.
- [26] Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. *J Exp Med* 1998;188:1849–57.
- [27] Gomes NA, Gattass CR, Barreto-De-Souza V, Wilson ME, DosReis GA. TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. *J Immunol* 2000;164:2001–8.
- [28] Kitani A, Chua K, Nakamura K, Strober W. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. *J Immunol* 2000;165:691–702.
- [29] Schneider H, et al. Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (extracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4(+) T cells from receptor/ligand-deficient mice. *J Immunol* 2002;169:3475–9.
- [30] Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. *Nat Immunol* 2002;3:135–42.
- [31] McHugh RS, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. *Immunity* 2002;16:311–23.
- [32] Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived CD4(+)CD25(+) T regulatory cells: highly potent regulators of diabetes that require TRANCE-RANK signals. *Immunity* 2002;16:183–91.
- [33] Tzachanis D, et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. *Nat Immunol* 2001;2:1174–82.
- [34] Neurath MF, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. *J Exp Med* 2002;195:1129–43.
- [35] Hara M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. *J Immunol* 2001;166:3789–96.